These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 21112803

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Monitoring tyrosinaemia type I: Blood spot test for nitisinone (NTBC).
    Sander J, Janzen N, Terhardt M, Sander S, Gökcay G, Demirkol M, Ozer I, Peter M, Das AM.
    Clin Chim Acta; 2011 Jan 14; 412(1-2):134-8. PubMed ID: 20883679
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC.
    Thimm E, Richter-Werkle R, Kamp G, Molke B, Herebian D, Klee D, Mayatepek E, Spiekerkoetter U.
    J Inherit Metab Dis; 2012 Mar 14; 35(2):263-8. PubMed ID: 22069142
    [Abstract] [Full Text] [Related]

  • 6. Nitisinone: new drug. Type 1 tyrosinemia: an effective drug.
    Prescrire Int; 2007 Apr 14; 16(88):56-8. PubMed ID: 17458044
    [Abstract] [Full Text] [Related]

  • 7. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec.
    Larochelle J, Alvarez F, Bussières JF, Chevalier I, Dallaire L, Dubois J, Faucher F, Fenyves D, Goodyer P, Grenier A, Holme E, Laframboise R, Lambert M, Lindstedt S, Maranda B, Melançon S, Merouani A, Mitchell J, Parizeault G, Pelletier L, Phan V, Rinaldo P, Scott CR, Scriver C, Mitchell GA.
    Mol Genet Metab; 2012 Sep 14; 107(1-2):49-54. PubMed ID: 22885033
    [Abstract] [Full Text] [Related]

  • 8. The role of nitisinone in tyrosine pathway disorders.
    Lock E, Ranganath LR, Timmis O.
    Curr Rheumatol Rep; 2014 Nov 14; 16(11):457. PubMed ID: 25266991
    [Abstract] [Full Text] [Related]

  • 9. Tyrosinemia type 1 in Spain: mutational analysis, treatment and long-term outcome.
    Couce ML, Dalmau J, del Toro M, Pintos-Morell G, Aldámiz-Echevarría L, Spanish Working Group on Tyrosinemia type 1.
    Pediatr Int; 2011 Dec 14; 53(6):985-9. PubMed ID: 21752152
    [Abstract] [Full Text] [Related]

  • 10. First Scandinavian case of successful pregnancy during nitisinone treatment for type 1 tyrosinemia.
    Äärelä L, Nevalainen PI, Kurppa K, Hiltunen P.
    J Pediatr Endocrinol Metab; 2020 May 26; 33(5):661-664. PubMed ID: 32238608
    [Abstract] [Full Text] [Related]

  • 11. In brief: Nitisinone (Orfadin) for hereditary tyrosinemia.
    Med Lett Drugs Ther; 2016 Oct 10; 58(1505):e132. PubMed ID: 27701365
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1.
    De Laet C, Munoz VT, Jaeken J, François B, Carton D, Sokal EM, Dan B, Goyens PJ.
    Dev Med Child Neurol; 2011 Oct 10; 53(10):962-4. PubMed ID: 21745202
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [New drugs; nitisinone].
    Cohen AF, van Bronswijk H.
    Ned Tijdschr Geneeskd; 2006 Nov 18; 150(46):2541-2. PubMed ID: 17152330
    [Abstract] [Full Text] [Related]

  • 18. Discontinuation of NTBC after liver transplantation in tyrosinemia type 1.
    Kurihara K, Toyoda H, Amoano K, Inoue M, Uchida K, Sakurai H, Hayashi A, Hirayama M.
    Pediatr Int; 2018 Nov 18; 60(11):1039-1041. PubMed ID: 30375135
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Nitisinone in the treatment of hereditary tyrosinaemia type 1.
    McKiernan PJ.
    Drugs; 2006 Nov 18; 66(6):743-50. PubMed ID: 16706549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.